U.S. markets close in 7 minutes

uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference

~ Up to Two Years of Follow-up in Large Transgenic Huntington’s Disease Model Demonstrates Stable mHTT Protein Lowering ~

 ~ Novel Preclinical Data Demonstrates Successful Lowering of Pathogenic Exon 1 Fragment ~

~ Additional Data Demonstrates the Potential of MRS as Imaging Biomarker for Huntington’s Disease Gene-Therapy Studies ~

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of multiple new preclinical data on AMT-130, its investigational AAV gene therapy for the treatment of Huntington’s disease (HD), at the 15th Annual CHDI Huntington’s disease Therapeutics Conference in Palm Springs, California.

“Our data presentations at CHDI illustrate the increasing potential of AMT-130 to target the highly toxic exon 1 protein fragment, achieve broad vector biodistribution across several animal species and show meaningful activity using the presence of extracellular vesicles as a potential biomarker,” stated Sander van Deventer, M.D., Ph.D., executive vice president, research & product development of uniQure. “In addition, we highlight the use of magnetic resonance spectroscopy as a potentially important imaging biomarker to measure the restoration of target tissue. Collectively, these findings represent a robust package of new preclinical data to better inform how researchers and clinicians pursue a much-needed treatment for this devastating disease.”

Four scientific abstracts submitted by uniQure researchers were accepted for presentation at the conference, of which one is an oral presentation to be featured today. Important findings across several preclinical studies presented at the conference include the following:

Translatable Biomarkers in Gene Therapy for Huntington Disease: Learnings from Pre-clinical Studies

  • In identifying translatable biomarkers for gene therapy studies in Huntington’s disease, transgenic Huntington’s disease minipigs were used to assess the biodistribution and target engagement in a larger brain. The minipig model is the largest diseased animal model available, generally weighing up to 300 pounds.
     
  • AMT-130 was administered by MRI-guided convention-enhanced delivery (CED) at a single dose, bilaterally in the caudate and putamen. Vector DNA distribution and transgene expression in minipig brains demonstrated extensive brain coverage comparable at the two interim sacrifice timepoints of 6- and 12-months post administration, leading to significant lowering of mutant huntingtin (mHTT) protein in the brain.
     
  • At 12 months, the most pronounced mHTT protein lowering was observed in the putamen (85%), caudate (80%) and amygdala (78%), followed by thalamus (56%) and cerebral cortex (44%). The ongoing study that now includes up to two years of follow-up, demonstrated stable mHTT protein lowering of up to 30 percent in the cerebrospinal fluid (CSF) of minipigs after a single administration of AMT-130.

Secreted Therapeutics: Monitoring Durability of microRNA-based Gene Therapies in Huntington’s disease

  • Neurons derived from the induced pluripotent stem cells (iPSC) of Huntington’s disease patients were used to study the presence of extracellular therapeutic microRNA targeting human huntingtin (miHTT) after transduction with AMT-130. Extracellular vesicles were identified as carriers of RNA species, including microRNAs, and are therefore potential biomarkers for diagnosis and pharmacokinetics. Results from this new study demonstrated that therapeutic miHTT molecules are secreted in a dose-dependent manner from AMT-130-treated neuronal cells, providing the potential of a promising translational marker to monitor long-term expression of AMT-130 gene therapy in the brain.
     
  • To support these results, non-human primates received a single administration of AMT-130 resulting in widespread distribution of therapeutic miHTT molecules in both the striatum and cortex, as well as the presence of therapeutic miHTT molecules in the CSF up to 6 months after intrastriatal injection of AMT-130.

Lowering the Pathogenic Exon 1 HTT Fragment by AAV5-miHTT Gene Therapy

  • In a study using the Q175FDN mouse model, the target engagement of aberrantly spliced exon 1 HTT transcript (exon 1 HTT) was investigated. These new preclinical data demonstrated that the mice treated with AMT-130 experienced a dose-dependent lowering of exon 1 HTT mRNA in both the striatum and cortex, as well as the full-length HTT mRNA. The lowering was shown to be well correlated with the detected levels of vector DNA and mature miHTT molecules in the mice treated with AMT-130.

Exploring the Effects of Intrastriatal AAV5-miHTT Lowering Therapy on Neuronal Function, MRS Signal and Mutant Huntingtin Levels in the Q175FDN Mouse Model of Huntington’s disease

  • Magnetic resonance spectroscopy (MRS) data in the Q175FDN mouse model of Huntington’s disease demonstrate that levels of N-acetyl aspartate (NAA), a neuronal integrity marker, were restored in mice treated with the high dose of AMT-130, supporting the use of imaging biomarkers in gene therapy studies for Huntington’s disease. Importantly, effects of mHTT silencing in the Q175FDN model on MRS were complemented by additional data on striatal gene expression profiles, demonstrating a trend towards normalization with AMT-130 treatment. These new data build on earlier MRS and MRI data suggesting improvement in brain cell function, a reversal in Huntington’s disease neuropathology and a partial reversal of volume loss in the hippocampus, a key brain region involved in memory.

The uniQure data presentations featured at CHDI are available on the investor page of the Company’s website, www.uniQure.com

About Huntington’s Disease
Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioral abnormalities and cognitive decline, resulting in complete physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene, that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no therapies to delay the onset or to slow the disease’s progression.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether AMT-130 will target the highly toxic exon 1 protein fragment, achieve broad vector biodistribution across several animal species or show meaningful activity using the presence of extracellular vesicles as a potential biomarker, and whether magnetic resonance spectroscopy will be an important imaging biomarker to measure the restoration of target tissue. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators’ clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s Quarterly Report on Form 10-Q filed on October 28, 2019. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:    
     
FOR INVESTORS: FOR MEDIA:
     
Maria E. Cantor  Eva M. Mulder Tom Malone
Direct: 339-970-7536 Direct: +31 20 240 6103 Direct: 339-970-7558
Mobile: 617-680-9452 Mobile: +31 6 52 33 15 79 Mobile: 339-223-8541
m.cantor@uniQure.cm e.mulder@uniQure.com t.malone@uniQure.com

  • Coronavirus stock market rally triggers the dreaded 'death cross'
    Business
    Yahoo Finance

    Coronavirus stock market rally triggers the dreaded 'death cross'

    For the first time in over a year, the S&P 500 is seeing its 50-day moving average cross below its 200-day moving average (see Yahoo Finance chart below) points out SunDial Capital Research. This is known on Wall Street as the “death cross,” and is commonly believed to be a bearish short-term indicator for markets. Indeed, SunDial Capital Research has the historical data handy to back up the concerns.

  • Ready to buy back into this market? If so, forget about Apple and grab these stocks instead, strategist says
    Business
    MarketWatch

    Ready to buy back into this market? If so, forget about Apple and grab these stocks instead, strategist says

    The market is utterly underestimating how much of a shock the coronavirus is going to be to the economy. And I think for the next 12 months, the U.S. consumer is only going to spend his money or her money on [nondiscretionary] goods. So, within that basket, I think you have to let Apple go.

  • Profit Will Soon Double (Or More) At 11 Companies, Analysts Say
    Business
    Investor's Business Daily

    Profit Will Soon Double (Or More) At 11 Companies, Analysts Say

    Corporate profit is all but certain to drop in the first quarter as the coronavirus shuts America down. But analysts still think profit will double or more at some S&P 500 companies. Double profit?

  • ‘Selling fatigue’ has kicked in, but the capitulation and stock-market bottom may be yet to come, UBS says
    Business
    MarketWatch

    ‘Selling fatigue’ has kicked in, but the capitulation and stock-market bottom may be yet to come, UBS says

    Global stocks are edging lower, and oil prices have plunged to 17-year lows at the start of another week set to be dominated by the coronavirus pandemic. The investor optimism came despite President Trump extending the U.S. lockdown to April 30 and public health officials warning that the American death toll could be between 100,000 and 200,000, with cases in the millions. In our call of the day, UBS strategists said “selling fatigue” may have kicked in as investors were no longer reacting as wildly to incremental bad news as they have been in recent weeks.

  • JPMorgan: These 3 Stocks Are Poised to Surge by at Least 35%
    Business
    TipRanks

    JPMorgan: These 3 Stocks Are Poised to Surge by at Least 35%

    JPMorgan's Global Quantitative and Derivatives Strategy team, led by Marko Kolanovic, has been crunching the numbers on the coronavirus pandemic, and found that the forecasts can vary wildly, with predicted economic declines ranging from 20% to 70%, depending on which data the analyst chooses to start with. The JPMorgan report does offer a ray of hope: because the hospital numbers are a lagging indicator, it is possible that the social containment measures have taken hold and brought us closer to the inflection point – and that infection rates will soon start declining. Kolanovic writes, “Taking into account the unprecedented monetary and fiscal measures being implemented, as well as unprecedented asset declines over the past month, we maintain that asset price recovery is likely and our pre-pandemic equity price target for 2020 is achievable sometime in the first half of 2021.”

  • Is Boeing Stock A Buy Right Now? This Is What You Need To Know
    Business
    Investor's Business Daily

    Is Boeing Stock A Buy Right Now? This Is What You Need To Know

    Boeing earnings have evaporated as 737 Max deliveries and production are on hold and the coronavirus's spread hits air travel demand. Is Boeing stock a good buy now? Investors should look at the aerospace giant's fundamentals and the BA stock chart.

  • U.S. markets tick up amid coronavirus crisis
    Business
    Yahoo Finance Video

    U.S. markets tick up amid coronavirus crisis

    Yahoo Finance's Jared Blikre breaks down today's market action as investors fear a global coronavirus shutdown could last months.

  • Audacious Chinese coffee chain Luckin, not content in its quixotic battle against Starbucks, dreams of becoming ‘Amazon-like’
    Business
    MarketWatch

    Audacious Chinese coffee chain Luckin, not content in its quixotic battle against Starbucks, dreams of becoming ‘Amazon-like’

    The Chinese startup that has reshaped the coffee sector here, wiping away Starbucks' dominance in the country, is leaping into an untraditional foray — one that is sure to perpetuate questions about its long-term strategy. Nasdaq-listed Luckin Coffee (LK) came out of nowhere in 2017 and swiftly ate into Starbucks' (SBUX) domination of China sales, with its intuitive mobile app, ubiquitous grab-and-go stores, and discounts so deep that they have frustrated some investors. One conspicuous example of Luckin's cutthroat strategy was the building of hundreds of its stores within mere meters of existing Starbucks locations, often right next door.

  • Is Abbott A Buy After FDA Blesses Not One — But Two — Coronavirus Tests?
    Business
    Investor's Business Daily

    Is Abbott A Buy After FDA Blesses Not One — But Two — Coronavirus Tests?

    So, while the medical company's sales and earnings have grown consistently for several years, Abbott isn't lining up with CAN SLIM rules for investing. Investors are advised to seek companies with recent quarterly earnings and sales growth of 20%-25%. The bigger, the better.

  • Shares of a German Ventilator Manufacturer Are Soaring
    Business
    Bloomberg

    Shares of a German Ventilator Manufacturer Are Soaring

    A crushing global shortage of ventilators needed to treat coronavirus patients has sent a German smallcap stock soaring, leaving analysts scrambling to value both the shares and the company's ability to help combat the crisis. While major German indexes have lost between 17% and 30% in 2020, shares of Draegerwerk AG & Co KGaA have gained about 80%, taking off in mid-March after Germany ordered 10,000 ventilators and other medical equipment from the company. M.M. Warburg analyst Eggert Kuls estimates that each ventilator costs about 20,000 euros, making the deal worth 200 million euros ($221 million) in revenue for Draeger.

  • Business
    Barrons.com

    Warren Buffett’s $10 Billion Bet on Occidental Petroleum Is Looking More Dicey

    (BRKA)'s $10 billion preferred stock investment in (OXY) is looking more troubled. Two Wall Street analysts say that an embattled Occidental (ticker: OXY) may choose to pay the $800 million in annual dividends in stock rather than in cash. Paying the dividend in common stock, as permitted under the terms of the deal, would be dilutive to Occidental.

  • Dow Jones Rallies 600 Points As Coronavirus Drug Hopes Boost Stock Market
    Business
    Investor's Business Daily

    Dow Jones Rallies 600 Points As Coronavirus Drug Hopes Boost Stock Market

    Key market indexes held most of their gains heading into the last hour of trading Monday, with the Dow Jones Industrial Average up more than 600 points. The Nasdaq rallied 3.3%, the S&P 500 rose 3.2% and the Dow Jones industrials gained 2.9% in the stock market today. Volume was mixed, lower on the NYSE but higher on the Nasdaq, vs. the same time Friday.

  • Saudi to raise oil exports to record levels as price war rages
    Business
    AFP

    Saudi to raise oil exports to record levels as price war rages

    Saudi Arabia said on Monday it will raise its oil exports to a record 10.6 million barrels per day starting from May despite a global supply glut, escalating a price war with Russia. Oil prices are languishing at 17-year lows as the coronavirus pandemic threatens a painful global recession that could further sap demand. Saudi Arabia, the world's top oil exporter which already announced a sharp production increase for April, said it would add additional supplies to the global market, deepening a glut.

  • How Soon Will You Get Your Coronavirus Stimulus Check?
    Business
    MoneyWise

    How Soon Will You Get Your Coronavirus Stimulus Check?

    The IRS will base your payment on the most recent tax return you filed. If you haven't filed your 2019 return yet — and you now have until July 15 to do that — the tax agency will pull up your 2018 filing. If you earned too much during 2018 to receive a payment but would qualify based on last year's income, because it was lower, you'll want to file your 2019 return quickly.

  • China's Lifting of Restrictions Has Worked, Flu Expert Says
    World
    Bloomberg

    China's Lifting of Restrictions Has Worked, Flu Expert Says

    China's lifting of restrictions related to the coronavirus has been successful, according to research by Imperial College in London. "As movement increased and China restarted their economy, we didn't see an increase in transmission," says Dr. Kylie Ainslie, research associate in influenza dynamics in the Department of Infectious Disease Epidemiology at Imperial. She speaks on "Bloomberg Markets: European Open."

  • Tesla stock rally: shares rise with the stock market
    Business
    Insider Monkey

    Tesla stock rally: shares rise with the stock market

    Tesla's stock rally continued today as analysts debate the company's long-term prospects. Several analysts have cut their price targets for the company as deliveries are expected to be lower than expected before the coronavirus pandemic hit. However, some have upgraded their position on Tesla Inc.

  • Here are the best bets for investors seeking income, according to Goldman Sachs
    Business
    MarketWatch

    Here are the best bets for investors seeking income, according to Goldman Sachs

    The stimulus bill signed into law Friday keeps any companies that borrow from the government from paying dividends to shareholders for at least a year after the loan is repaid — even as bond yields have collapsed to to near all-time lows. The provisions of the CARE Act likely exacerbate a trend of companies trying to keep as much cash on hand as possible as the economic downturn worsens. The Goldman strategists estimate dividends for S&P 500 stocks will decline 25% to $44 per share in 2020, and note 12 companies, ranging from Apache Corp. (APA)  to Old Dominion Freight Line (ODFL), have already reduced or suspended their shareholder payouts.

  • Tax filing deadline 2020: When are my state taxes due?
    Business
    USA TODAY

    Tax filing deadline 2020: When are my state taxes due?

    Uncle Sam is offering tax payers some relief by delaying the federal tax deadline to this summer, but you still need to double check when your state taxes are due. The federal income tax filing deadline has been pushed to July 15 from April 15 to give Americans more breathing room in the wake of the coronavirus pandemic. The Alabama Department of Revenue announced that the due date for individual tax filings is the same date as the corresponding federal income tax return on July 15.

  • Investors shouldn't let a stock market sucker's rally fool them
    Business
    Yahoo Finance

    Investors shouldn't let a stock market sucker's rally fool them

    The sucker's rally on Wall Street is in full effect in large part because Wall Street's powerful high-speed trading computers are completely mentally detached from the harsh realities breaking out on Main Street during the coronavirus pandemic. So in short, consider fading last week's rip in equities. But oh what a rip higher it was, folks, as traders got their pounds of flesh from the Federal Reserve (unlimited QE program) and government (a $2 trillion-plus fiscal relief package).

  • Business
    Reuters

    U.S. crude prices at Texas slide to near $10, lowest since late 1998

    The United States' flagship crude oil grade plunged on Monday to trade at about $10 a barrel, the weakest since late 1998 as demand plummeted due to the coronavirus pandemic and storage filled quickly. The grade, priced at the heart of the Permian basin in Midland, Texas, traded at $9.50 below benchmark prices, traders said, bringing the outright price to near $10 a barrel. West Texas Intermediate crude (WTI) at Midland, along with other actively traded U.S. crude oil grades, have sharply weakened since the coronavirus pandemic has restricted the movement of billions of people around the world and shriveled energy demand.

  • Ford And GM Do Not Care Much About Electric Vehicle Production
    Business
    Benzinga

    Ford And GM Do Not Care Much About Electric Vehicle Production

    The promise that electric vehicles (EVs) hold in the automobile market hinges on two major factors – that they will decrease tailpipe emissions and they will be more economical to operate than internal combustion engine (ICE) vehicles. With analysts lowering their outlook for global oil demand in the second quarter of 2020 due to the COVID-19 epidemic, it is certain that the operating cost of ICE vehicles will be comparable to that of EVs. The memo looks to have reached major U.S. auto companies, with detailed production plans for North America showing Ford Motor Company (NYSE: F) and General Motors Company (NYSE: GM) forecasting to produce more than five million SUVs and pickup trucks in 2026, while only planning to make 320,000 EVs the same year.

  • No, your 401(k) isn’t doomed. Yes, you can use this crazy market to help turn it around
    Business
    MarketWatch

    No, your 401(k) isn’t doomed. Yes, you can use this crazy market to help turn it around

    Consider: If you're like most regular U.S. investors, you have most or even all of your stock market investments tied to just one index: The S&P 500 (SPY) which tracks the 500 biggest companies in America. It's the biggest index in the world, and the one that most mutual funds follow when they offer a plain vanilla “U.S. stock market fund.” In the past month the S&P 500—even counting the latest rally—has fallen 17%.

  • Tesla will make Medtronic ventilators at New York gigafactory
    U.S.
    American City Business Journals

    Tesla will make Medtronic ventilators at New York gigafactory

    Medtronic, which is trying to boost production of ventilators used to help the sickest COVID-19 patients, will get an assist from automaker Tesla Inc., which will convert a New York production plant to churn out medical devices instead of solar power cells. Ishrak said that Tesla would be making "one of the products that we make, that is not our prime product right now [but] one that is perfectly suitable at least in some of these instances." RELATED: The U.S. tried to build a new fleet of ventilators.

  • The stock market might not bottom until the VIX comes down — here’s why the volatility gauge remains stubbornly high
    Business
    MarketWatch

    The stock market might not bottom until the VIX comes down — here’s why the volatility gauge remains stubbornly high

    Here's one reason stock-market investors aren't convinced the bear-market rout triggered by the global COVID-19 pandemic hasn't bottomed out: a stubbornly high reading for an index known as the VIX. A closely watched measure of stock-market volatility often used as a proxy for investor anxiety, the Cboe Volatiity Index (VIX) typically referred to by its ticker, was lower Monday at 58.74. “While the S&P 500 rallied 20%+ from its low during the week, VIX remained stubbornly elevated along with stock implied correlations,” said Julian Emanuel, chief equity and derivatives strategist at BTIG, in a Sunday note.

  • ViacomCBS Inc, A Nostalgic Powerhouse
    Business
    Insider Monkey

    ViacomCBS Inc, A Nostalgic Powerhouse

    Furthermore, the company also owns the rights to multiple sports leagues and popular franchises such as Star Trek, Mission Impossible and Shrek, as well as individual beloved films such as Forrest Gump. It is undeniable that ViacomCBS has a hold on many beloved names, however, how does this make it a great long-term stock idea? Untapped Assets and the Shift to Streaming Before we jump into a more technical look at what makes this stock a valuable addition to any long-term portfolio, we need to explore a couple of concepts.